• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Pharmacokinetics of piperacillin during continuous ambulatory peritoneal dialysis].

作者信息

Ryckelynck J P, Debruyne D, Hurault De Ligny B, Moulin M

机构信息

Service de Néphrologie, CHU Clemenceau, Caen.

出版信息

Pathol Biol (Paris). 1988 May;36(5):507-10.

PMID:3043348
Abstract

We studied the kinetics of piperacillin in patients under continuous ambulatory peritoneal dialysis. Piperacillin 2 g was injected intravenously in 6 patients whereas 1 g was given intraperitoneally either a single dose in 3 patients without infection or the same dose every six-hours in 4 patients with peritonitis. Piperacillin was assayed by HPLC. After intravenous administration, the mean plasma piperacillin concentration was 3.1 +/- 5.6 mg/l at 12 h, the mean plasma t1/2 at 2.43 +/- 0.84 h, the volume of distribution at 20.4 +/- 6.3 l and the peritoneal clearance at 0.19 +/- 0.04 ml/min. After iterative intraperitoneal administration, serum and dialysate concentrations of piperacillin were above the minimum inhibitory concentration for susceptible pathogens without antibiotic accumulation. Peritoneal absorption was higher during peritonitis (83.4 +/- 4.8%) than without peritonitis (67.8 +/- 8.5%). Piperacillin 2 g IV every 8 hours or 1 g IP every 6 hours seemed to be the appropriate regimen in patients with chronic renal failure on CAPD.

摘要

相似文献

1
[Pharmacokinetics of piperacillin during continuous ambulatory peritoneal dialysis].
Pathol Biol (Paris). 1988 May;36(5):507-10.
2
Pharmacokinetics of intravenous and intraperitoneal fosfomycin in continuous ambulatory peritoneal dialysis.
Clin Nephrol. 1988 Jan;29(1):35-40.
3
Pharmacokinetics of piperacillin in patients on peritoneal dialysis with and without peritonitis.哌拉西林在伴有或不伴有腹膜炎的腹膜透析患者中的药代动力学。
J Pharm Sci. 1990 Feb;79(2):99-102. doi: 10.1002/jps.2600790204.
4
Transperitoneal movement and pharmacokinetics of cefotiam and cefsulodin in patients on continuous ambulatory peritoneal dialysis.
Clin Nephrol. 1988 Oct;30(4):197-206.
5
Pharmacokinetics of intravenous and intraperitoneal ceftriaxone in chronic ambulatory peritoneal dialysis.
Eur J Clin Pharmacol. 1986;31(4):479-83. doi: 10.1007/BF00613528.
6
Use of bolus intraperitoneal aminoglycosides for treating peritonitis in end-stage renal disease patients receiving continuous ambulatory peritoneal dialysis and continuous cycling peritoneal dialysis.在接受持续性非卧床腹膜透析和持续性循环腹膜透析的终末期肾病患者中,使用大剂量腹腔内氨基糖苷类药物治疗腹膜炎。
Adv Perit Dial. 2000;16:280-4.
7
[Pharmacokinetics of ceftazidime injected peritoneally in continuous ambulatory peritoneal dialysis].[持续非卧床腹膜透析患者腹腔注射头孢他啶的药代动力学]
Pathol Biol (Paris). 1986 May;34(5):328-31.
8
[Treatment of peritonitis under continuous ambulatory peritoneal dialysis using intraperitoneal ceftazidime].[持续非卧床腹膜透析时腹腔内使用头孢他啶治疗腹膜炎]
Pathol Biol (Paris). 1989 Jun;37(5 Pt 2):681-4.
9
Pharmacokinetics of intraperitoneal piperacillin/tazobactam in patients on peritoneal dialysis with and without pseudomonas peritonitis.接受腹膜透析的患者,无论有无铜绿假单胞菌性腹膜炎,腹腔注射哌拉西林/他唑巴坦的药代动力学
Perit Dial Int. 2000 Mar-Apr;20(2):227-31.
10
Comparison of the pharmacokinetics of piperacillin and sulbactam during intermittent and continuous intravenous infusion.哌拉西林和舒巴坦在间歇静脉输注和持续静脉输注期间的药代动力学比较。
Chemotherapy. 2007;53(5):370-7. doi: 10.1159/000107725. Epub 2007 Sep 3.

引用本文的文献

1
Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.持续非卧床腹膜透析患者的药物治疗。临床药代动力学考量。
Clin Pharmacokinet. 1990 Feb;18(2):104-17. doi: 10.2165/00003088-199018020-00002.